Almotriptan

Almotriptan, a triptan, interacts potently with 5-HT1B and 5-HT1D receptors, exhibiting low or no affinity for other 5-HT receptor subtypes, adrenergic, dopaminergic, muscarinic cholinergic, and benzodiazepine receptors. The drug's clinical efficacy correlates with its affinity for 5-HT1B and 5-HT1D receptors, suggesting a key role in the acute relief of migraine attacks.

Adult

Start with 6.25-12.5 mg PO. If needed in 2 hours, a second dose may be administered.

Pediatric

Child ">=12 years": Start with 6.25-12.5 mg PO. If needed in 2 hours, a second dose may be administered. Efficacy for the treatment of migraine-associated symptoms of nausea, photophobia, and phonophobia was not established for adolescents.

Renal adjustment

Reduce dose in renal impairment

Hepatic adjustment

Reduce dose in hepatic impairment

Max dose

2 doses/24 hours and 25 mg/24 hours

• Ischemic coronary artery disease
• Vasospastic coronary artery disease
• Significant underlying cardiovascular disease
• Cerebrovascular syndromes
• Peripheral vascular disease
• Uncontrolled hypertension
• Hemiplegic migraine
• Basilar migraine
• Concomitant use with ergotamine-containing medication
• Concomitant use with ergot-type medication
• Concomitant use with any other 5-HT agonist (triptans)
• Concomitant use with methylene blue
• Concomitant use with or within 2 weeks of discontinuing an MAO inhibitor
• Concomitant use with linezolid
• Ischemic heart disease
• Coronary artery vasospasm
• Exposure to MAO inhibitor within preceding 2 weeks
• Within 24 hours of another triptan
• Within 24 hours of an ergot derivative
• Within 24 hours of SSRIs
• Within 24 hours of SNRIs